Abstract
Despite the availability of antimicrobial agents and vaccines, community-acquired pneumonia remains a serious problem. Severe forms tend to occur in very young children and among the elderly, since their immune competence is eroded by immaturity and immune senescence, respectively. The main etiologic agents differ according to patient age and geographic area. Streptococcus pneumoniae, Haemophilus influenzae, respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV-3) are the most important pathogens in children, whereas influenza viruses are the leading cause of fatal pneumonia in the elderly. Effective vaccines are available against some of these organisms. However, there are still many agents against which vaccines are not available or the existent ones are suboptimal. To tackle this problem, empiric approaches are now being systematically replaced by rational vaccine design. This is facilitated by the growing knowledge in the fields of immunology, microbial pathogenesis and host response to infection, as well as by the availability of sophisticated strategies for antigen selection, potent immune modulators and efficient antigen delivery systems. Thus, a new generation of vaccines with improved safety and efficacy profiles compared to old and new agents is emerging. In this chapter, an overview is provided about currently available and new vaccination concepts.
Chapter PDF
Similar content being viewed by others
Keywords
- Influenza Virus
- Respiratory Syncytial Virus
- Severe Acute Respiratory Syndrome
- Influenza Vaccine
- Conjugate Vaccine
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Girard MP, Cherian T, Pervikov Y, Kieny MP (2006) A review of vaccine research and development: Human acute respiratory infections. Vaccine 24: 4692–4700
Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C (2002) Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2: 25–32
Schmid D, Rouse B (2005) Respiratory viral vaccines. In: J Mestecky, M Lamm, W Strober, J Bienenstock, J McGhee, L Mayer (eds): Mucosal Immunology. Elsevier Inc., Philadelphia, 923–936
Stohr K, Esveld M (2004) Public health. Will vaccines be available for the next influenza pandemic? Science 306: 2195–2196
Kemble G, Greenberg H (2003) Novel generations of influenza vaccines. Vaccine 21: 1789–1795
Palache AM, Scheepers HS, de Regt V, van Ewijk P, Baljet M, Brands R, van Scharrenburg GJ (1999) Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev Biol Stand 98: 115–125; discussion 133-114
Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G, Dorner F (1999) Development of a Vero cell-derived influenza whole virus vaccine. Dev Biol Stand 98: 101–110; discussion 111
Brands R, Visser J, Medema J, Palache AM, van Scharrenburg GJ (1999) Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand 98: 93–100; discussion 111
Bullough PA, Hughson FM, Skehel JJ, Wiley DC (1994) Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371: 37–43
Belshe R, Maassab H, Mendelman P (2004) Influenza vaccine-live. In: S Plotkin, W Orenstein (eds): Vaccines. Elsevier Inc., Philadelphia, 371–388
Cox RJ, Brokstad KA, Ogra P (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1–15
Belshe RB (2004) Current status of live attenuated influenza virus vaccine in the US. Virus Res 103: 177–185
Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, Wittes J, Bryant M (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18: 899–906
Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J, Walker R, Hessel C, Cho I, Mendelman PM (2004) Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 39: 920–927
Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI et al (2000) Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181: 1133–1137
Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB (2004) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 53: 1–40
Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB (2005) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 54: 1–40
Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H et al (2004) Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res 103: 187–193
Schumacher R, Adamina M, Zurbriggen R, Bolli M, Padovan E, Zajac P, Heberer M, Spagnoli GC (2004) Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 22: 714–723
Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ (2005) Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24: 4475–4481
Cassetti MC, Couch R, Wood J, Pervikov Y (2005) Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004. Vaccine 23: 1529–1533
Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157–1163
Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W (2004) A “universal” human influenza A vaccine. Virus Res 103: 173–176
Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM et al (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993–3003
Durbin AP, Karron RA (2003) Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis 37: 1668–1677
Tao T, Skiadopoulos MH, Durbin AP, Davoodi F, Collins PL, Murphy BR (1999) A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Vaccine 17: 1100–1108
Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89: 405–421
Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140: 543–546
Simoes EA (2002) Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 3 (Suppl 1): S26–33
Munoz FM, Piedra PA, Glezen WP (2003) Safety and immunogenicity of respi ratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21: 3465–3467
Piedra PA, Grace S, Jewell A, Spinelli S, Hogerman DA, Malinoski F, Hiatt PW (1998) Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J 17: 217–224
Plotnicky H, Siegrist CA, Aubry JP, Bonnefoy JY, Corvaia N, Nguyen TN, Power UF (2003) Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. Vaccine 21: 2651–2660
Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus AD, de Groot R, Corvaia N, Beck A, Bouveret-Le-Cam N et al (2001) Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 184: 1456–1460
Power UF, Plotnicky H, Blaecke A, Nguyen TN (2003) The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B. Vaccine 22: 168–176
Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL et al (2000) Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 182: 1331–1342
Schmidt AC, McAuliffe JM, Murphy BR, Collins PL (2001) Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 75: 4594–4603
Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA (2004) Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 78: 11198–11207
Peiris JS, Guan Y, Yuen KY (2004) Severe acute respiratory syndrome. Nat Med 10: S88–97
Jiang S, He Y, Liu S (2005) SARS vaccine development. Emerg Infect Dis 11: 1016–1020
Holmes KV (2003) SARS-associated coronavirus. N Engl J Med 348: 1948–1951
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450–454
Wong SK, Li W, Moore MJ, Choe H, Farzan M (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2 J Biol Chem 279: 3197–3201
Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ (2004) A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428: 561–564
Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, Huang X, Lu S (2005) Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 79: 1906–1910
Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL (2004) Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363: 2122–2127
Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y et al (2004) Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78: 12672–12676
Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P et al (2004) Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363: 938–947
Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, Lanzavecchia A, Nabel GJ (2005) Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 102: 797–801
Zhu MS, Pan Y, Chen HQ, Shen Y, Wang XC, Sun YJ, Tao KH (2004) Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol Lett 92: 237–243
Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL (2004) Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 101: 9804–9809
Howell MR, Nang RN, Gaydos CA, Gaydos JC (1998) Prevention of adenoviral acute respiratory disease in Army recruits: cost-effectiveness of a military vaccination policy. Am J Prev Med 14: 168–175
Schmidt AC, Couch RB, Galasso GJ, Hayden FG, Mills J, Murphy BR, Chanock RM (2001) Current research on respiratory viral infections: Third International Symposium. Antiviral Res 50: 157–196
Janoff E, Briles D, Rubins J (2005) Respiratory bacterial vaccines. In: J Mestecky, M Lamm, W Strober, J Bienenstock, J McGhee, L Mayer (eds), Mucosal Immunology. Elsevier Inc, Philadelphia, 905–921
Fedson D, Musher D (2004) Pneumococcal polysaccharide. In: S Plotkin, W Orenstein (eds): Vaccines. Elsevier Inc., Philadelphia, 529–588
Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, Lindblad I, Sundelof B, Kalin M (1998) Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 351: 399–403
Munoz FM, Englund JA, Cheesman CC, Maccato ML, Pinell PM, Nahm MH, Mason EO, Kozinetz CA, Thompson RA, Glezen WP (2001) Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 20: 826–837
Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N (2003) A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349: 1341–1348
Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P (2003) Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 22: 10–16
Eskola D, Black S, Shinefield H (2004) Pneumococcal conjugate vaccine. In: S Plotkin, W Orenstein (eds): Vaccines. Elsevier Inc., Philadelphia, 589–624
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D et al (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737–1746
Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R (2004) Pneumococcal vaccines: an update on current strategies. Vaccine 22: 2209–2220
Shapiro ED, Ward JI (1991) The epidemiology and prevention of disease caused by Haemophilus influenzae type b. Epidemiol Rev 13: 113–142
Peltola H, Kayhty H, Virtanen M, Makela PH (1984) Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 310: 1561–1566
Robbins JB, Schneerson R, Anderson P, Smith DH (1996) The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. Jama 276: 1181–1185
Decker MD, Edwards KM (1998) Haemophilus influenzae type b vaccines: history, choice and comparisons. Pediatr Infect Dis J 17: S113–116
Mulholland EK, Hoestermann A, Ward JI, Maine N, Ethevenaux C, Greenwood BM (1996) The use of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian infants. Vaccine 14: 905–909
Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, Weber M, Palmer A, Schneider G, Jobe K et al (1997) Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 349: 1191–1197
Heath PT (1998) Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 17: S117–122
Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine OS, Levine MM (1996) Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 15: 216–222
Akkoyunlu M, Janson H, Ruan M, Forsgren A (1996) Biological activity of serum antibodies to a nonacylated form of lipoprotein D of Haemophilus influenzae. Infect Immun 64: 4586–4592
Kyd JM, Dunkley ML, Cripps AW (1995) Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 63: 2931–2940
Hotomi M, Yamanaka N, Shimada J, Suzumoto M, Ikeda Y, Sakai A, Arai J, Green B (2002) Intranasal immunization with recombinant outer membrane protein P6 induces specific immune responses against nontypeable Haemophilus influenzae. Int J Pediatr Otorhinolaryngol 65: 109–116
Bertot GM, Becker PD, Guzman CA, Grinstein S (2004) Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis 189: 1304–1312
Baraff LJ, Cody CL, Cherry JD (1984) DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 73: 31–36
Sato Y, Kimura M, Fukumi H (1984) Development of a pertussis component vaccine in Japan. Lancet 1: 122–126
AdHocGroupfortheStudyofPertussisVaccines (1988) Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 331: 955–960
Storsaeter J, Hallander H, Farrington CP, Olin P, Mollby R, Miller E (1990) Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 8: 457–461
Guiso N, Boursaux-Eude C, Weber C, Hausman SZ, Sato H, Iwaki M, Kamachi K, Konda T, Burns DL (2001) Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine 19: 3248–3252
Campins-Marti M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang LM, Mertsola J, Oselka G, Ward J, Wirsing von Konig CH et al (2001) Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 20: 641–646
Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N (2001) Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 39: 4396–4403
Denoel P, Godfroid F, Guiso N, Hallander H, Poolman J (2005) Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetellapertussis variant isolates in a mouse model. Vaccine 23: 5333–5341
van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, Bondeson K, von Konig CH, Riffelmann M, Vahrenholz C, Guiso N et al (2005) Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J Clin Microbiol 43: 2837–2843
Penttila T, Vuola JM, Puurula V, Anttila M, Sarvas M, Rautonen N, Makela PH, Puolakkainen M (2000) Immunity to Chlamydia pneumoniae induced by vaccination with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2). Vaccine 19: 1256–1265
Penttila T, Tammiruusu A, Liljestrom P, Sarvas M, Makela PH, Vuola JM, Puolakkainen M (2004) DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model. Vaccine 22: 3386–3394
Pinchuk I, Starcher BC, Livingston B, Tvninnereim A, Wu S, Appella E, Sidney J, Sette A, Wizel B (2005) A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae. J Immunol 174: 5729–5739
Finco O, Bonci A, Agnusdei M, Scarselli M, Petracca R, Norais N, Ferrari G, Garaguso I, Donati M, Sambri V et al (2005) Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings. Vaccine 23: 1178–1188
Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, Mariani M, Manetti R, Agnusdei M, Cevenini R et al (2002) Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun 70: 368–379
Yang YP, Myers LE, McGuinness U, Chong P, Kwok Y, Klein MH, Harkness RE (1997) The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies. FEMS Immunol Med Microbiol 17: 187–199
Chen D, McMichael JC, VanDerMeid KR, Hahn D, Mininni T, Cowell J, Eldridge J (1996) Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect Immun 64: 1900–1905
McMichael JC (2000) Progress toward the development of a vaccine to prevent Moraxella (Branhamella) catarrhalis infections. Microbes Infect 2: 561–568
Jiao X, Hirano T, Hou Y, Gu XX (2002) Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect Immun 70: 5982–5989
Yu S, Gu XX (2005) Synthesis and characterization of lipooligosaccharidebased conjugate vaccines for serotype B Moraxella catarrhalis. Infect Immun 73: 2790–2796
Baseman JB, Tully JG (1997) Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis 3: 21–32
Smith CB, Friedewald WT, Chanock RM (1967) Inactivated Mycoplasma pneumoniae vaccine. Evaluation in volunteers. Jama 199: 353–358
Waites KB, Talkington DF (2004) Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 17: 697–728
Brenner DJ, Steigerwalt AG, McDade JE (1979) Classification of the Legionnaires’ disease bacterium: Legionella pneumophila, genus novum, species nova, of the family Legionellaceae, familia nova. Ann Intern Med 90: 656–658
McDade JE, Shepard CC, Fraser DW, Tsai TR, Redus MA, Dowdle WR (1977) Legionnaires’ disease: isolation of a bacterium and demonstration of its role in other respiratory disease. N Engl J Med 297: 1197–1203
Blander SJ, Horwitz MA (1989) Vaccination with the major secretory protein of Legionella pneumophila induces cell-mediated and protective immunity in a guinea pig model of Legionnaires’ disease. J Exp Med 169: 691–705
Eisenstein TK, Tamada R, Meissler J, Flesher A, Oels HC (1984) Vaccination against Legionella pneumophila: serum antibody correlates with protection induced by heat-killed or acetone-killed cells against intraperitoneal but not aerosol infection in guinea pigs. Infect Immun 45: 685–691
Ricci ML, Torosantucci A, Scaturro M, Chiani P, Baldassarri L, Pastoris MC (2005) Induction of protective immunity by Legionella pneumophila flagellum in an A/J mouse model. Vaccine 23: 4811–4820
Friedman H, Klein TW, Widen R, Newton C, Blanchard DK, Yamamoto Y (1988) Legionella pneumophila immunity and immunomodulation: nature and mechanisms. Adv Exp Med Biol 239: 327–341
Blander SJ, Horwitz MA (1993) Major cytoplasmic membrane protein of Legionella pneumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires’ disease. J Clin Invest 91: 717–723
Yoon WS, Park SH, Park YK, Park SC, Sin JI, Kim MJ (2002) Comparison of responses elicited by immunization with a Legionella species common lipoprotein delivered as naked DNA or recombinant protein. DNA Cell Biol 21: 99–107
Weeratna R, Stamler DA, Edelstein PH, Ripley M, Marrie T, Hoskin D, Hoffman PS (1994) Human and guinea pig immune responses to Legionella pneumophila protein antigens OmpS and Hsp60. Infect Immun 62: 3454–3462
Blander SJ, Breiman RF, Horwitz MA (1989) A live avirulent mutant Legionella pneumophila vaccine induces protective immunity against lethal aerosol challenge. J Clin Invest 83: 810–815
Cryz SJ Jr, Furer E, Cross AS, Wegmann A, Germanier R, Sadoff JC (1987) Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest 80: 51–56
Cryz SJ Jr, Sadoff JC, Ohman D, Furer E (1988) Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. J Lab Clin Med 111: 701–707
Cryz SJ Jr, Wedgwood J, Lang AB, Ruedeberg A, Que JU, Furer E, Schaad UB (1994) Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J Infect Dis 169: 1159–1162
Cryz SJ Jr, Lang A, Rudeberg A, Wedgwood J, Que JU, Furer E, Schaad U (1997) Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst Mitt 38: 345–349
Schaad UB, Lang AB, Wedgwood J, Ruedeberg A, Que JU, Furer E, Cryz SJ, Jr (1991) Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 338: 1236–1237
Lang AB, Schaad UB, Rudeberg A, Wedgwood J, Que JU, Furer E, Cryz SJ, Jr (1995) Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 127: 711–717
Lang AB, Rudeberg A, Schoni MH, Que JU, Furer E, Schaad UB (2004) Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 23: 504–510
Zuercher AW, Imboden MA, Jampen S, Bosse D, Ulrich M, Chtioui H, Lauterburg BH, Lang AB (2005) Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol 142: 381–387
Larbig M, Mansouri E, Freihorst J, Tummler B, Kohler G, Domdey H, Knapp B, Hungerer KD, Hundt E, Gabelsberger J et al (2001) Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 19: 2291–2297
Gocke K, Baumann U, Hagemann H, Gabelsberger J, Hahn H, Freihorst J, von Specht BU (2003) Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol Med Microbiol 37: 167–171
Pier G (2005) Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev Vaccines 4: 645–656
Plotkin SA (2005) Vaccines: past, present and future. Nat Med 11: S5–11
Plotkin SA (2005) Six revolutions in vaccinology. Pediatr Infect Dis J 24: 1–9
Lambert PH, Liu M, Siegrist CA (2005) Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 11: S54–62
Plotkin SA (2003) Vaccines, vaccination, and vaccinology. J Infect Dis 187: 1349–1359
Mora M, Veggi D, Santini L, Pizza M, Rappuoli R (2003) Reverse vaccinology. Drug Discov Today 8: 459–464
Singh U, Shah PH, MacFarlane RC (2004) DNA content analysis on microarrays. Methods Mol Biol 270: 237–248
De Groot AS, Sbai H, Aubin CS, McMurry J, Martin W (2002) Immunoinformatics: Mining genomes for vaccine components. Immunol Cell Biol 80: 255–269
Sette A, Livingston B, McKinney D, Appella E, Fikes J, Sidney J, Newman M, Chesnut R (2001) The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29: 271–276
Rappuoli R, Covacci A (2003) Reverse vaccinology and genomics. Science 302: 602
Rappuoli R (2000) Reverse vaccinology. Curr Opin Microbiol 3: 445–450
Stech J, Garn H, Wegmann M, Wagner R, Klenk HD (2005) A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med 11: 683–689
Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ (2004) Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J Virol 78: 1851–1857
Wood JM, Robertson JS (2004) From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2: 842–847
Subbarao K, Katz JM (2004) Influenza vaccines generated by reverse genetics. Curr Top Microbiol Immunol 283: 313–342
Kaiser J (2004) Influenza: girding for disaster. Facing down pandemic flu, the world’s defenses are weak. Science 306: 394–397
Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11: S45–53
Schoen C, Stritzker J, Goebel W, Pilgrim S (2004) Bacteria as DNA vaccine carriers for genetic immunization. Int J Med Microbiol 294: 319–335
Vajdy M, Srivastava I, Polo J, Donnelly J, O’Hagan D, Singh M (2004) Mucosal adjuvants and delivery systems for protein-, DNA-and RNA-based vaccines. Immunol Cell Biol 82: 617–627
Eko FO, He Q, Brown T, McMillan L, Ifere GO, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM et al (2004) A novel recombinant multisubunit vaccine against Chlamydia. J Immunol 173: 3375–3382
Duncan J, Gilley R, Schafer D, Moldoveanu Z, Mestecky J (1996) Poly(lactideco-glycolide) microencapsulation of vaccines for mucosal immunization. In: H Kiyono, P Ogra, J McGhee (eds): Mucosal Vaccines. Academic Press, Inc., San Diego, 159–173
Tomasi M, Hearn T (1996) ISCOMs, liposomes, and oil-based vaccine delivery systems. In: H Kiyono, P Ogra, J McGhee (eds): Mucosal Vaccines. Academic Press, Inc., San Diego, 175–186
Copland MJ, Rades T, Davies NM, Baird MA (2005) Lipid based particulate formulations for the delivery of antigen. Immunol Cell Biol 83: 97–105
Seo JY, Seong SY, Ahn BY, Kwon IC, Chung H, Jeong SY (2002) Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect Immun 70: 1143–1149
de Wit E, Munster VJ, Spronken MI, Bestebroer TM, Baas C, Beyer WE, Rimmelzwaan GF, Osterhaus AD, Fouchier RA (2005) Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol 79: 12401–12407
Arnold H, Bumann D, Felies M, Gewecke B, Sorensen M, Gessner JE, Freihorst J, von Specht BU, Baumann U (2004) Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprFOprI from Pseudomonas aeruginosa. Infect Immun 72: 6546–6553
Langermann S, Palaszynski SR, Burlein JE, Koenig S, Hanson MS, Briles DE, Stover CK (1994) Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. J Exp Med 180: 2277–2286
Ho PS, Kwang J, Lee YK (2005) Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production. Vaccine 23: 1335–1342
Turner MS, Giffard PM (1999) Expression of Chlamydia psittaci-and human immunodeficiency virus-derived antigens on the cell surface of Lactobacillus fermentum BR11 as fusions to bspA. Infect Immun 67: 5486–5489
Bender BS, Rowe CA, Taylor SF, Wyatt LS, Moss B, Small PA, Jr (1996) Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 70: 6418–6424
Czub M, Weingartl H, Czub S, He R, Cao J (2005) Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23: 2273–2279
Eko FO, Witte A, Huter V, Kuen B, Furst-Ladani S, Haslberger A, Katinger A, Hensel A, Szostak MP, Resch S et al (1999) New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine 17: 1643–1649
Haidinger W, Szostak MP, Jechlinger W, Lubitz W (2003) Online monitoring of Escherichia coli ghost production. Appl Environ Microbiol 69: 468–474
Lubitz W, Witte A, Eko FO, Kamal M, Jechlinger W, Brand E, Marchart J, Haidinger W, Huter V, Felnerova D et al (1999) Extended recombinant bacterial ghost system. J Biotechnol 73: 261–273
Lubitz W (2001) Bacterial ghosts as carrier and targeting systems. Expert Opin Biol Ther 1: 765–771
Szostak MP, Mader H, Truppe M, Kamal M, Eko FO, Huter V, Marchart J, Jechlinger W, Haidinger W, Brand E et al (1997) Bacterial ghosts as multifunctional vaccine particles. Behring Inst Mitt 98: 191–196
Witte A, Wanner G, Sulzner M, Lubitz W (1992) Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol 157: 381–388
Matzinger P (2002) The danger model: a renewed sense of self. Science 296: 301–305
Mader HJ, Szostak MP, Hensel A, Lubitz W, Haslberger AG (1997) Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine 15: 195–202
Igietseme J, Eko F, He Q, Bandea C, Lubitz W, Garcia-Sastre A, Black C (2005) Delivery of Chlamydia vaccines. Expert Opin Drug Deliv 2: 549–562
Garcea RL, Gissmann L (2004) Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol 15: 513–517
Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK (2001) Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 75: 9713–9722
Niikura M, Takamura S, Kim G, Kawai S, Saijo M, Morikawa S, Kurane I, Li TC, Takeda N, Yasutomi Y (2002) Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 293: 273–280
Shi W, Liu J, Huang Y, Qiao L (2001) Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 75: 10139–10148
Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T (2000) Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 18: 1327–1333
Bungener L, Huckriede A, Wilschut J, Daemen T (2002) Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci Rep 22: 323–338
Bungener L, Idema J, ter Veer W, Huckriede A, Daemen T, Wilschut J (2002) Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J Liposome Res 12: 155–163
Plant A, Williams NA (2004) Modulation of the immune response by the cholera-like enterotoxins. Curr Top Med Chem 4: 509–519
Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M et al (2005) Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97: 181–188
Rharbaoui FG, CA (2005) New generation of immune modulators based on Toll-like receptors signaling. Curr Immunol Reviews 1: 107–118
Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G (2001) Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19: 2534–2541
Sanchez J, Wallerstrom G, Fredriksson M, Angstrom J, Holmgren J (2002) Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. J Biol Chem 277: 33369–33377
Lu X, Clements JD, Katz JM (2002) Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 20: 1019–1029
van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR (2000) Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165: 4778–4782
Gockel CM, Russell MW (2005) Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein. Immunology 116: 477–486
Areas AP, Oliveira ML, Miyaji EN, Leite LC, Aires KA, Dias WO, Ho PL (2004) Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun 321: 192–196
Sabirov A, Kodama S, Hirano T, Suzuki M, Mogi G (2001) Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Infect Immun 69: 2964–2971
Medina E, Talay SR, Chhatwal GS, Guzman CA (1998) Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route. Eur J Immunol 28: 1069–1077
Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20: 197–216
Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A (2005) The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 102: 9577–9582
Chuang TH, Lee J, Kline L, Mathison JC, Ulevitch RJ (2002) Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol 71: 538–544
Wagner H (2004) The immunobiology of the TLR9 subfamily. Trends Immunol 25: 381–386
Lee CJ, Lee LH, Gu XX (2005) Mucosal immunity induced by pneumococcal glycoconjugate. Crit Rev Microbiol 31: 137–144
Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I et al (2004) Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22: 3136–3143
von Hunolstein C, Mariotti S, Teloni R, Alfarone G, Romagnoli G, Orefici G, Nisini R (2001) The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconju gates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine 19: 3058–3066
Deiters U, Muhlradt PF (1999) Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage inflammatory protein 1alpha (MIP-1alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infiltration in mice. Infect Immun 67: 3390–3398
Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G (1997) Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 185: 1951–1958
Deiters U, Gumenscheimer M, Galanos C, Muhlradt PF (2003) Toll-like receptor 2-and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses. Infect Immun 71: 4456–4462
Into T, Kiura K, Yasuda M, Kataoka H, Inoue N, Hasebe A, Takeda K, Akira S, Shibata K (2004) Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation. Cell Microbiol 6: 187–199
Link C, Gavioli R, Ebensen T, Canella A, Reinhard E, Guzman CA (2004) The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur J Immunol 34: 899–907
Rharbaoui F, Drabner B, Borsutzky S, Winckler U, Morr M, Ensoli B, Muhlradt PF, Guzman CA (2002) The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 32: 2857–2865
Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 18: 927–974
Ebensen T, Paukner S, Link C, Kudela P, de Domenico C, Lubitz W, Guzman CA (2004) Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol 172: 6858–6865
Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ, Frazer IH (2001) Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20: 862–869
Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, Ulmer JB, Liu MA (1995) Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1: 583–587
Prince AM, Whalen R, Brotman B (1997) Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 15: 916–919
Reddy ST, Ertl HC (1999) The potential use of DNA vaccines for neonatal immunization. Curr Opin Mol Ther 1: 22–29
Ozaki T, Yauchi M, Xin KQ, Hirahara F, Okuda K (2005) Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant. Viral Immunol 18: 373–380
Miyaji EN, Dias WO, Tanizaki MM, Leite LC (2003) Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol 37: 53–57
Ochsenbein AF, Pinschewer DD, Sierro S, Horvath E, Hengartner H, Zinkernagel RM (2000) Protective long-term antibody memory by antigendriven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc Natl Acad Sci USA 97: 13263–13268
Zinkernagel RM (2002) On differences between immunity and immunological memory. Curr Opin Immunol 14: 523–536
Pinschewer DD, Perez M, Jeetendra E, Bachi T, Horvath E, Hengartner H, Whitt MA, de la Torre JC, Zinkernagel RM (2004) Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest 114: 988–993
Nicol M, Huebner R, Mothupi R, Kayhty H, Mbelle N, Khomo E (2002) Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheriatetanus-whole cell pertussis vaccine: a randomized trial. Pediatr Infect Dis J 21: 138–141
Cassidy WM, Watson B, Ioli VA, Williams K, Bird S, West DJ (2001) A randomized trial of alternative two-and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 107: 626–631
Ahman H, Kayhty H, Vuorela A, Leroy O, Eskola J (1999) Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 17: 2726–2732
Bosnak M, Dikici B, Bosnak V, Haspolat K (2002) Accelerated hepatitis B vaccination schedule in childhood. Pediatr Int 44: 663–665
Goldblatt D, Miller E, McCloskey N, Cartwright K (1998) Immunological response to conjugate vaccines in infants: follow up study. BMJ 316: 1570–1571
Siegrist CA (2001) Neonatal and early life vaccinology. Vaccine 19: 3331–3346
Pihlgren M, Tougne C, Bozzotti P, Fulurija A, Duchosal MA, Lambert PH, Siegrist CA (2003) Unresponsiveness to lymphoid-mediated signals at the neonatal follicular dendritic cell precursor level contributes to delayed germinal center induction and limitations of neonatal antibody responses to T-dependent antigens. J Immunol 170: 2824–2832
Pihlgren M, Schallert N, Tougne C, Bozzotti P, Kovarik J, Fulurija A, Kosco-Vilbois M, Lambert PH, Siegrist CA (2001) Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur J Immunol 31: 939–946
Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M, Newport MJ, Aaby P, Whittle H, Lambert PH et al (2002) Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 168: 919–925
Van de Perre P (2003) Transfer of antibody via mother’s milk. Vaccine 21: 3374–3376
Quiambao BP, Nohynek H, Kayhty H, Ollgren J, Gozum L, Gepanayao CP, Soriano V, Makela PH (2003) Maternal immunization with pneumococcal polysaccharide vaccine in the Philippines. Vaccine 21: 3451–3454
Daly KA, Toth JA, Giebink GS (2003) Pneumococcal conjugate vaccines as maternal and infant immunogens: challenges of maternal recruitment. Vaccine 21: 3473–3478
Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD (1991) The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325: 1453–1460
Bjorkholm B, Hagberg L, Sundbeck G, Granstrom M (2000) Booster effect of low doses of tetanus toxoid in elderly vaccinees. Eur J Clin Microbiol Infect Dis 19: 195–199
Powers DC, Belshe RB (1994) Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and “original antigenic sin”. J Infect Dis 169: 1125–1129
Smith DJ, Forrest S, Ackley DH, Perelson AS (1999) Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA 96: 14001–14006
Voordouw AC, Sturkenboom MC, Dieleman JP, Stijnen T, Smith DJ, van der Lei J, Stricker BH (2004) Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. Jama 292: 2089–2095
Rammensee HG (2003) Immunoinformatics: bioinformatic strategies for better understanding of immune function. Introduction. Novartis Found Symp 254: 1–2
Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213–219
Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H (2001) PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 53: 87–94
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Becker, P.D., Guzmán, C.A. (2007). Community-acquired pneumonia: paving the way towards new vaccination concepts. In: Community-Acquired Pneumonia. Birkhäuser Advances in Infectious Diseases. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7563-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-7643-7563-8_10
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7562-1
Online ISBN: 978-3-7643-7563-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)